7 Results for "

modified pyrimidines

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "modified pyrimidines" in MCE Product Catalog:

17
17 Cited Publications
Cat. No.: HY-B0083
CAS No.: 75706-12-6
Synonyms: HWA486; RS-34821; SU101
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
loading...
    loading...
Cat. No.: HY-E70575
CAS No.: 118390-70-8
Target:  

DNA Glycosylase

Research Areas:  

Others

Endonuclease VIII is a DNA repair enzyme that excises oxidized pyrimidines from DNA. Endonuclease VIII is a bacterial DNA glycosylase/AP lyase that excises modified pyrimidines, including thymine glycol (Tg), uracil glycol, dihydrothymine, dihydrouracil (DHU) .
loading...
    loading...
Cat. No.: HY-B0083S
CAS No.: 1189987-23-2
Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent .
loading...
    loading...
Cat. No.: HY-B0083R
CAS No.: 75706-12-6
Synonyms: HWA486 (Standard); RS-34821 (Standard); SU101 (Standard)
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
loading...
    loading...
Cat. No.: HY-B0083S1
Synonyms: HWA486-13C6; RS-34821-13C6; SU101-13C6
Leflunomide- 13C6 (HWA486- 13C6) is 13C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
loading...
    loading...
Cat. No.: HY-184013
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

SU0617 is a selective SMUG1 inhibitor with a human IC50 of 1.5 μM. SU0617 inhibits base excision repair activity of SMUG1, including excision of modified and damaged pyrimidines from DNA. SU0617 can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-L044
586 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 586 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).